Home > Insider Trading > Filing (0000899243-22-033322)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1830214	Ginkgo Bioworks Holdings Inc.	DNA	Biological Products, (No Disgnostic Substances) (2836)	872652913

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1873507	E. Mark Dmytruk	C/O Ginkgo Bioworks Holdings, Inc. 27 Drydock Avenue Boston MA 02210	See Remarks	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Class A Common Stock	Acquisiton	2022-10-05	618,242	$0.00	627,344	No	4	M	Direct
Class A Common Stock	Disposition	2022-10-06	279,255	$3.25	348,089	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Class A Common Stock	Class B Common Stock	Disposition	2022-10-05	618,242	$0.00	0	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
39,891			No	4	M	Direct

Footnotes

Represents the conversion of shares of Class B Common Stock to shares of Class A Common Stock.
Represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligation to be funded by a "sell to cover" transaction.
Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date.
Excludes restricted stock units, which were previously reported as shares of Class B common stock on the Form 4 filed by the reporting person on March 14, 2022. Because the Issuer has the ability to settle such restricted stock units with shares of Class A common stock or cash upon vesting, restricted stock units will be reported separately from shares of Class B Common Stock in future reports.